Analysts await Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

They expect $-0.24 EPS, up 83.33% or $0.2 from last year’s $-0.44 per share.

At the moment 5 analysts are watching Caladrius Biosciences, Inc. (NASDAQ:CLBS), 1 rate it “Buy”, 1 “Outperform”, 3 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 4 analysts have a mean sales target of 6.51 million. For the quarter ending Jun-16, 4 analysts have a mean sales target of 7.12 million whilst for the year ending Dec-16, 5 analysts have a mean target of 29.16 million.

In terms of earnings per share, 4 analysts have a -0.44 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 4 analysts have a -0.20 EPS mean target and for the quarter ending Jun-16 there are 5 estimates of -0.99 EPS.

The biggest institutional shareholders in Caladrius Biosciences, Inc. include Great Point Partners LLC which owns 2 million shares in the company valued at $3.35 million. Pine River Capital Management, L.P. is the second biggest holder with 1 million shares currently valued at 1.49 million whilst Vanguard Group Inc has 1 million shares valued at 1.80 million.

Total shares held by institutions as of the most recent company filings are 7,687,405 with a reported 219,225 bought and 918,690 sold. These holdings make up 13.75% of the company’s outstanding shares.

Currently insiders hold 10,025,093 shares in the business which makes up 18.10% of shares. The biggest holder currently is Robert Aholt,Jr who owns 4,369,317 shares (7.89% of those outstanding), whilst Dr. Wayne A. Marasco,M.D. holds 1,436,713 (2.59% of shares outstanding) and Dr. David J. Mazzo, PhD holds 463,384 (0.84% of shares outstanding).

The stock increased 14.4681% or $0.1201 during the last trading session, hitting $1.0900. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has fallen 71.56% over the past 6 months and is downtrending.